PE-backed Victory Capital goes public

By Iris Dorbian — 2 weeks ago

Cleveland-based Victory Capital Holdings Inc, an asset management firm, has raised $152.1 million for its IPO after pricing its 11.7 million shares at $13 per share. The stock began trading February 8, 2018 on the NASDAQ under the ticker symbol “VCTR.” J.P. Morgan, BofA Merrill Lynch and Morgan Stanley are the lead underwriters. Victory Capital is backed by Crestview Partners and Reverence Capital Partners.

Continue

PE-backed FTSI goes public

By Iris Dorbian — 2 weeks ago

Fort Worth, Texas-based FTS International, a provider of hydraulic fracturing services, has debuted its IPO of 19.5 million shares at $18 per share. The stock began trading February 2, 2018 on the New York Stock Exchange under the ticker symbol “FTSI.” Credit Suisse and Morgan Stanley are the lead underwriters. FTSI’s backers include RRJ Capital and Temasek.

Continue

Armo Biosciences raises about $128 mln for IPO

By Iris Dorbian — 3 weeks ago

Redwood City, California-based Armo BioSciences Inc, a late-stage immuno-oncology company has raised about $128 million for its IPO after pricing its over 7.5 million shares at $17 per share. The stock began trading January 26, 2018 on the NASDAQ under the ticker symbol “ARMO.” Jefferies LLC, Leerink Partners LLC and BMO Capital Markets Corp are the lead underwriters. Armo’s pre-IPO backers were Qiming Venture Partners, Decheng Capital, Sequoia Capital, Quan Capital, RTW Investments, Kleiner Perkins Caufield and Byers, OrbiMed, DAG Ventures, NanoDimension, HBM Healthcare Investments and GV.

Continue

Bain Capital-backed Solid Biosciences rolls out IPO

By Iris Dorbian — 3 weeks ago

Cambridge, Massachusetts-based Solid Biosciences, which is focused on treating Duchenne muscular dystrophy, has raised $125 million after pricing its IPO of over 7.8 million at $16 per share. The stock began trading January 26, 2018 on the NASDAQ under the ticker symbol “SLDB.” J.P. Morgan, Goldman Sachs and Leerink Partners are the lead underwriters. Solid Biosciences’ pre-IPO backers include RA Capital Management, Bain Capital Life Sciences, RTW Investments, Foresite Capital, Cormorant Asset Management LLC, Perceptive Advisors and Janus Capital Management.

Continue

ResTORbio debuts IPO

By Iris Dorbian — 3 weeks ago

Boston-based ResTORbio Inc, a clinical-stage biopharmaceutical company focused on treating aging-related diseases, has debuted its IPO after pricing its over 5.6 million shares at $15 per share. The stock began trading January 26, 2018 on the NASDAQ under the ticker symbol “TORC.” BofA Merrill Lynch, Leerink Partners and Evercore ISI are the lead underwriters. ResTORbio’s pre-IPO includes include OrbiMed, Fidelity Management & Research Company, Rock Springs Capital, Quan Capital and Nest Bio.

Continue

Apollo-backed PlayAGS goes public

By Iris Dorbian — 3 weeks ago

PlayAGS, a maker of electronic gaming machines and other products and services for the gaming industry, has raised $164 million after pricing its IPO of 10.25 million shares at $16 per share. The stock began trading January 26, 2018 on the New York Stock Exchange under the ticker symbol “AGS.” Credit Suisse, Deutsche Bank Securities, Jefferies and Macquarie Capital are the lead underwriters. PlayAGS is owned by Apollo Global Management.

Continue

VC-backed Menlo Therapeutics goes public

By Iris Dorbian — 4 weeks ago

Menlo Park, California-based Menlo Therapeutics Inc, a pharmaceutical company focused on treating chronic pruritus and chronic cough, has raised $119 million for its IPO after pricing its 7 million shares at $17 per share. The stock began trading January 25, 2018 on the NASDAQ under the ticker symbol “MNLO.” Jefferies LLC, Piper Jaffray & Co. and Guggenheim Securities LLC are the lead underwriters. The investors included VenBio, Novo Holdings A/S, Rock Springs Capital, Aisling Capital, Bay City Capital, Vivo Capital, Presidio Partners, Remeditex and F-Prime Capital.

Continue

PE-backed FTSI sets IPO pricing terms

By Iris Dorbian — 4 weeks ago

Fort Worth, Texas-based FTS International, a provider of hydraulic fracturing services, has priced its over 15 million shares at between $15 and $18 per share. The stock will trade on the New York Stock Exchange under the ticker symbol “FTSI.” Credit Suisse and Morgan Stanley are the lead underwriters. FTSI’s backers include RRJ Capital and Temasek.

Continue